An evidence-based assessment of the NCEP adult treatment panel II guidelines

JAMA

Volumn 282, Issue 21, 1999, Pages 2051-2057

  Ansell, Benjamin J ^a   Watson, Karol E ^b   Fogelman, Alan M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033485528     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.21.2051     Document Type: Review

References (60)

1. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
2. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
3. Blankenhom DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
4. Brown C, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
5. Rifkind BM. Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Am J Cardiol. 1984;43:30C-34C
6. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990;323:946-955.
7. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality. BMJ. 1990;301:309-314.
8. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Circulation. 1995;91:2274-2282.
9. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313-321.
10. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Eur Heart J. 1998;19:1434-1503.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994; 344:1383-1389.
12. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
14. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. Circulation. 1997;95:1683-1685.
15. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality. BMJ. 1990;301:309-314.
16. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615-1622.
18. Post Coronary Bypass Graft Trial Investigators. The effects of aggressive lowering of low-density lipoprotein cholesterol and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
19. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and the reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
20. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341:70-76.
21. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998;97:1446-1452.
22. Goldbourt U, Yaari S, Medalie JH. Isolated low HOL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107-113.
23. Pedersen TR, Kjekshus J, Berg K, et al. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study. Lancet. 1995;345:1274-1275.
24. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
25. Tracy RE, Newman WP III, Wattgney WA, Berenson GS. Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study. Am J Med Sci. 1995;310:S37-S41.
26. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650-1656.
27. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening test for preventing coronary heart disease in adults. Ann Intern Med. 1996;124:515-517.
28. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill Book Co; 1989:1215-1250.
29. Rifkind BM, Schucker B, Gorder DJ. When should patients with heterozygous familial hypercholesterolemia be treated? JAMA. 1999;281:180-181.
30. Stein EA, Illingworth DR, Kwiterovitch PO, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. JAMA. 1999;281:137-144.
31. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
32. Hulley S, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
33. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction. J Am Coll Cardiol. 1998;32:140-146.
34. American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1998.
35. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med. 1998;129:681-689.
36. Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 1997;96:4211-4218.
37. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
38. Kesnaniemi YA. Serum triglycerides and clinical benefit in lipid-lowering trials. Am J Cardiol. 1998; 81:70B-73B.
39. Thiery J, Seidel D. Safety and effectiveness of long-term LDL apheresis in patients at high risk. Curr Opin Lipidol. 1998;9:521-526.
40. Castro R, Queiros J, Fonseca I, et al. Therapy of post-renal transplantation hyperlipidaemia. Nephrol Dial Transplant. 1997;12:2140-2143.
41. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation. 1997;96:1398-1402.
42. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
43. Jaeger BR, Meiser B, Nagel D, et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation. 1997;96(suppl 2):154-158.
44. Jenkins GH, Grieve LA, Yacoub MH, Singer DR. Effect of simvastatin on ejection fraction in cardiac transplant recipients. Am J Cardiol. 1996;78:1453-1456.
45. Kakkis JL, Ke B, Dawson S, et al. Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats. J Surg Res. 1999; 69:393-398
46. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation, 1996;61:1469-1474.
47. Gotto AM Jr. Effects of pravastatin in heart transplant recipients. Curr Opin Lipidol. 1995;6:341-343.
48. Haffner S, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
49. American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statement). Diabetes Care. 1999;22:S56-S59.
50. Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904-910.
51. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 1995;155:50-55.
52. Probstfield JL, Margitic SE, Byington RP, et al. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol. 1995;76:47C-53C.
53. Byington RP, Furberg CD, Crouse JR III, Espeland MA, Bond MG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;76:54C-59C.
54. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Ann Intern Med. 1996;124:548-556.
55. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below average cholesterol levels on the progression of carotid atherosclerosis. Circulation. 1998;97:1784-1790.
56. de Groot E, Jukema JW, van Swijndregt ADM, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings. J Am Coll Cardiol. 1998;31:1561-1567.
57. Crouse JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157:1305-1310.
58. Crouse JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction. Atherosclerosis. 1998;138:11-24.
59. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. Stroke. 1997:28; 946-950.
60. Pahor M, Elam MB, Garrison RJ, et al. . Emerging noninvasive biochemical markers to predict cardiovascular risk. Arch Intern Med. 1999;159:237-245.